Literature DB >> 18514012

Functional effects of cardiac sympathetic denervation in neurogenic orthostatic hypotension.

Richard Imrich1, Basil A Eldadah, Oladi Bentho, Sandra Pechnik, Yehonatan Sharabi, Courtney Holmes, Ehud Grossman, David S Goldstein.   

Abstract

BACKGROUND: Diseases characterized by neurogenic orthostatic hypotension (NOH), such as Parkinson disease (PD) and pure autonomic failure (PAF), are associated with cardiac sympathetic denervation, as reflected by low myocardial concentrations of 6-[(18)F]fluorodopamine-derived radioactivity. We studied the impact of such denervation on cardiac chronotropic and inotropic function.
METHODS: Cardiac inotropic function was assessed by the pre-ejection period index and the systolic time ratio index in response to the directly acting beta-adrenoceptor agonist, isoproterenol, and to the indirectly acting sympathomimetic amine, tyramine, in patients with PD+NOH or PAF (PD+NOH/PAF group, N=13). We compared the results to those in patients with multiple system atrophy, which usually entails NOH with normal cardiac sympathetic innervation (MSA, N=15), and in normal control subjects (N=5).
RESULTS: The innervated and denervated groups did not differ in baseline mean pre-ejection period index or systolic time ratio index. Tyramine increased cardiac contractility in the MSA patients and controls but not in the PD+NOH/PAF group. For similar heart rate responses, the PD+NOH/PAF group required less isoproterenol (p<0.01) and had lower plasma isoproterenol levels (p<0.01) than did the MSA group.
CONCLUSIONS: Among patients with NOH those with cardiac sympathetic denervation have an impaired inotropic response to tyramine and exaggerated responses to isoproterenol. This pattern suggests that cardiac denervation is associated with decreased ability to release endogenous norepinephrine from sympathetic nerves and with supersensitivity of cardiac beta-adrenoreceptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18514012      PMCID: PMC2696021          DOI: 10.1016/j.parkreldis.2008.04.002

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  26 in total

1.  Pressor response to intravenous tyramine is a marker of cardiac, but not vascular, adrenergic function.

Authors:  Janice V Meck; David S Martin; Dominick S D'Aunno; Wendy W Waters
Journal:  J Cardiovasc Pharmacol       Date:  2003-01       Impact factor: 3.105

2.  Where to Q in PEP.

Authors:  Gary G Berntson; David L Lozano; Yun-Ju Chen; John T Cacioppo
Journal:  Psychophysiology       Date:  2004-03       Impact factor: 4.016

3.  Cardiac sympathetic denervation from the early stage of Parkinson's disease: clinical and experimental studies with radiolabeled MIBG.

Authors:  H Takatsu; H Nishida; H Matsuo; S Watanabe; K Nagashima; H Wada; T Noda; K Nishigaki; H Fujiwara
Journal:  J Nucl Med       Date:  2000-01       Impact factor: 10.057

4.  Systolic time intervals during lower body negative pressure.

Authors:  T B Graboys; F J Forlini; E D Michaelson
Journal:  J Appl Physiol       Date:  1974-09       Impact factor: 3.531

5.  Systolic time intervals in heart failure in man.

Authors:  A M Weissler; W S Harris; C D Schoenfeld
Journal:  Circulation       Date:  1968-02       Impact factor: 29.690

6.  Neurovascular dissociation with paradoxical forearm vasodilation during systemic tyramine administration.

Authors:  Giris Jacob; Fernando Costa; Simi Vincent; David Robertson; Italo Biaggioni
Journal:  Circulation       Date:  2003-04-21       Impact factor: 29.690

7.  Cardiac sympathetic denervation in Parkinson disease.

Authors:  D S Goldstein; C Holmes; S T Li; S Bruce; L V Metman; R O Cannon
Journal:  Ann Intern Med       Date:  2000-09-05       Impact factor: 25.391

8.  Cardiovascular indices of peripheral and central sympathetic activation.

Authors:  H Schächinger; M Weinbacher; A Kiss; R Ritz; W Langewitz
Journal:  Psychosom Med       Date:  2001 Sep-Oct       Impact factor: 4.312

Review 9.  Usefulness of systolic time intervals in coronary artery disease.

Authors:  R P Lewis; H Boudoulas; T G Welch; W F Forester
Journal:  Am J Cardiol       Date:  1976-04       Impact factor: 2.778

Review 10.  Clinical overview of the synucleinopathies.

Authors:  Maria J Martí; Eduardo Tolosa; Jaume Campdelacreu
Journal:  Mov Disord       Date:  2003-09       Impact factor: 10.338

View more
  8 in total

Review 1.  Management of Supine Hypertension Complicating Neurogenic Orthostatic Hypotension.

Authors:  Jacquie Baker; Kurt Kimpinski
Journal:  CNS Drugs       Date:  2017-08       Impact factor: 5.749

2.  Cardiocirculatory manifestations in Parkinson's disease patients without orthostatic hypotension.

Authors:  T Pérez; B Tijero; I Gabilondo; A Luna; V Llorens; K Berganzo; M Acera; A Gonzalez; A Sanchez-Ferro; E Lezcano; J J Zarranz; J C Gómez-Esteban
Journal:  J Hum Hypertens       Date:  2015-01-29       Impact factor: 3.012

Review 3.  Cardiovascular dysautonomia in Parkinson disease: from pathophysiology to pathogenesis.

Authors:  Samay Jain; David S Goldstein
Journal:  Neurobiol Dis       Date:  2011-11-04       Impact factor: 5.996

4.  Clinical characteristics of supine hypertension in de novo Parkinson disease.

Authors:  Tadashi Umehara; Hiromasa Matsuno; Chizuko Toyoda; Hisayoshi Oka
Journal:  Clin Auton Res       Date:  2015-11-27       Impact factor: 4.435

Review 5.  Neurogenic orthostatic hypotension: a pathophysiological approach.

Authors:  David S Goldstein; Yehonatan Sharabi
Journal:  Circulation       Date:  2009-01-06       Impact factor: 29.690

Review 6.  Roles of cardiac sympathetic neuroimaging in autonomic medicine.

Authors:  David S Goldstein; William P Cheshire
Journal:  Clin Auton Res       Date:  2018-07-30       Impact factor: 4.435

7.  Dopamine D2R Agonist-Induced Cardiovascular Effects in Healthy Male Subjects: Potential Implications in Clinical Settings.

Authors:  Khalid Abou Farha; Corine Baljé-Volkers; Wim Tamminga; Izaak den Daas; Sandra van Os
Journal:  ISRN Neurol       Date:  2014-01-22

Review 8.  Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa.

Authors:  Stuart H Isaacson; Julia Skettini
Journal:  Vasc Health Risk Manag       Date:  2014-04-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.